Advertisement

Skin Manifestations of Systemic Bacterial Infections

  • Pascal del Giudice
  • Olivier Chosidow
  • The clinical manifestations of a systemic bacterial infection may be caused directly by the bacteria and/or by its toxins.

  • Secondary locations of bacteremias occur mainly during the course of endocarditis or septic vasculitis during acute or chronic meningococcaemia and gonococcaemia.

  • Ecthyma gangrenosum is a particular form of secondary septic location occurring mainly in neutropenic subjects and mainly caused by Pseudomonas aeruginosa.

  • Toxinic manifestations are mainly caused by Staphylococcus aureus, responsible for toxic shock syndrome and staphylococcal scalded skin syndrome, and Streptococcus pyogenes, responsible for streptococcal toxic shock syndrome and scarlet fever.

  • Purpura fulminans is a particular severe form of bacterial sepsis associated with vasculopathy and necrosis of the extremity.

Keywords

Necrotizing Fasciitis Toxic Shock Syndrome Skin Manifestation Scarlet Fever Purpura Fulminans 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Parikh SK, Lieberman A, Colbert DA, Slivers DN, Grossman ME. The identification of methicillin-resistant Staphylococcus aureus in Osler's nodes and Janeway lesions of acute bacterial endocarditis. J Am Acad Dermatol 1996; 35: 767–8.PubMedCrossRefGoogle Scholar
  2. 2.
    Maestre A, Mora A, Gutiérrez F, Hidalgo AM, Monmeneu JV, Mirete C, López F. Diagnosis: a Janeway lesion and an Osler's node. Clin Infect Dis 2001; 32: 63, 149.PubMedCrossRefGoogle Scholar
  3. 3.
    Gil MP, Velasco M, Botella JE, Ballester JE, Pedro F, Aliaga A. Janeway lesions: differential diagnosis with Osler's nodes. Int J Dermatol 1993; 32: 673.PubMedCrossRefGoogle Scholar
  4. 4.
    Cardullo AC, Silvers D, Grossman ME. Janeway lesions and Osler's nodes: a review of histopathologic findings. J Am Acad Dermatol 1990; 22: 1088–90.PubMedCrossRefGoogle Scholar
  5. 5.
    Vinson RP, Chung A, Elston DM, Keller RA. Septic micro-emboli in a Janeway lesion of bacterial endocarditis. J Am Acad Dermatol 1996; 35: 984–5.PubMedCrossRefGoogle Scholar
  6. 6.
    Rosenstein NE, Perkins BA, Stephens DS, Popovic T, Hughes JM. Meningococcal disease. N Engl J Med 2001; 344: 1378–87.PubMedCrossRefGoogle Scholar
  7. 7.
    Awad A. Diagnosis of meningococcal septicaemia. Lancet 2001; 357: 145.PubMedCrossRefGoogle Scholar
  8. 8.
    Nielsen HE, Andersen AE, Andersen J, Bottiger B, Christiansen KM, Daugjberg P, Larsen SO, Lind I, Nir M, Olofsson K. Diagnostic assessment of haemorrhagic rash and fever. Arch Dis Child 2001; 85: 160–5.PubMedCrossRefGoogle Scholar
  9. 9.
    Cartolano GL, Barbier C, Anoult D, Ricome JL, Hayon. Fatal acute cellulitis due to Neisseiria meningitidis. J Clin Microbiol 2003; 41: 3996–7.PubMedCrossRefGoogle Scholar
  10. 10.
    Assiert H, Chosidow O, Rekacewicz I, Lionnet F, Pipau FG, Riou JY, Revuz J. Chronic meningococcemia in acquired immunodeficiency infection. J Am Acad Dermatol 1993; 29 (5 pt 1): 793–4.CrossRefGoogle Scholar
  11. 11.
    Harwood CA, Stevens JC, Orton D, Bull RC, Paige D, Lessing MP, Mortimer PS, Marsden RA, Cerio R. Chronic meningococcaemia: a forgotten meningococcal disease. Br J Dermatol 2005; 153: 669–71.PubMedCrossRefGoogle Scholar
  12. 12.
    Benoit FL. Chronic meningococcemia. Case report and review of the literature. Am J Med 1963; 35: 103–12.Google Scholar
  13. 13.
    Mastrolonardo M, Loconsole F, Conte A, Rantuccio F. Cutaneous vasculitis as the sole manifestation of disseminated gonococcal infection: case report. Genitourin Med 1994; 70: 130–1.PubMedGoogle Scholar
  14. 14.
    O'Brien JP, Goldenberg DL, Rice PA. Disseminated gonococcal infection: a prospective analysis of 49 patients and a review of pathophysiology and immune mechanisms. Medicine (Baltimore) 1983; 62: 395–406.CrossRefGoogle Scholar
  15. 15.
    Kerle KK, Mascola JR, Miller TA. disseminated gonococcal infection. Am Fam Physician 1992; 45: 209–14.PubMedGoogle Scholar
  16. 16.
    Gomperts BN, White LK. Gonococcal hand abscess. Pediatr Infect Dis J 2000; 19: 671–2.PubMedCrossRefGoogle Scholar
  17. 17.
    Güçlüer H, Ergun T, Demirçay Z. Ecthyma gangrenosum. Int J Dermatol 1999; 38: 298–305.CrossRefGoogle Scholar
  18. 18.
    Boisseau AM, Sarlangue J, Perel Y, Hehunstre JP, Taïeb A, Malville J. Perineal ecthyma gangrenosum in infancy and early chidhood: septicemic and nonsepticemic forms. J Am Acad Dermatol 1992; 27: 415–8.PubMedCrossRefGoogle Scholar
  19. 19.
    Berger TG, Kaveh S, Becker D, Hoffman J. Cutaneous manifestations of Pseudomonas infections in AIDS. J Am Acad Dermatol 1995; 32: 279–80.PubMedCrossRefGoogle Scholar
  20. 20.
    Sevinsky LD, Viecens C, Ballesteros DO, Stengel F. Ecthyma gangrenosum: a cutaneous manifestation of Pseudomonas aeruginosa sepsis. J Am Acad Dermatol 1993; 29: 104–6.PubMedCrossRefGoogle Scholar
  21. 21.
    Greene SL, Su D, Muller SA. Ecthyma gangrenosum: report of clinical, histopathologic, and bacteriologic aspects of eight cases. J Am Acad Dermatol 1984; 11: 781–7.PubMedCrossRefGoogle Scholar
  22. 22.
    El Baze P, Thyss A, Caldani, Juhlin L, Scheider M, Ortonne JP. Pseudomonas O11 folliculitis: development into ecthyma gangrenosum in immunosuppressed patients. Arch Dermatol 1985; 121: 873–6.PubMedCrossRefGoogle Scholar
  23. 23.
    Becherel PA, Chosidow O, Berger E, Martin S, Khayat D, Herson S, Frances C. Granulocyte-macrophage colony-stimulating factor in the management of severe ecthyma gangrenosum related to myelodysplastic syndrome. Arch Dermatol 1995; 131: 892–4.PubMedCrossRefGoogle Scholar
  24. 24.
    Del Giudice P, Cua E, Bernard E, Chichmanian RM, Oregionni O, Brucker F, Dellamonica P. Pseudomonas aeruginosa ecthyma gangrenosum and facial cellulitis complicating carbi-mazole-induced agranulocytosis. Arch Dermatol 2006; 142: 1663–4.CrossRefGoogle Scholar
  25. 25.
    Chapman CB, Whorton M. Acute generalized miliary tuberculosis in adults. A clinicopathological study based on sixty-three cases diagnosed at autopsy. N Engl J Med 1946; 235: 239–248.Google Scholar
  26. 26.
    Schermer DR, Simpson CG, Haserick JR, Van Ordstrand HS. Tuberculosis cutis miliaris acuta generalisata. Report of a case in an adult and review of the literature. Arch Dermatol 1969; 99: 64–69.Google Scholar
  27. 27.
    Kennedy C, Knowles GK. Miliary tuberculosis presenting with skin lesions. Br Med J 1975; 3: 356.PubMedCrossRefGoogle Scholar
  28. 28.
    Fisher JR. Miliary tuberculosis with unusual cutaneous manifestations. JAMA 1978; 238: 241–242.CrossRefGoogle Scholar
  29. 29.
    Rietbroek RC, Dahlmans RPM, Smedts F, Frantzen PJ, Koopman RJJ, van Der Meer JWM. Tuberculosis cutis miliaris disseminata as a manifestation of miliary tuberculosis: literature review and report of a case of recurrent skin lesions. Clin Infect Dis 1991; 13: 265–269.Google Scholar
  30. 30.
    Del Giudice P, Bernard E, Perrin C, Bernardin G, Fouché R, Boissy C, Durant J, Dellamonica P. Unusual cutaneous manifestations of miliary tuberculosis. Clin Infect Dis 2000; 30: 201–204.PubMedCrossRefGoogle Scholar
  31. 31.
    Stack RJ, Bickley LK, Coppel IG. Miliary tuberculosis presenting as skin lesions in a patient with acquired immunode-ficiency syndrome. J Am Acad Dermatol 1990; 23: 1031–1035.PubMedCrossRefGoogle Scholar
  32. 32.
    Rohatgi PK, Palazzolo JV, Saini NB. Acute miliary tuberculosis of the skin in acquired immunodeficiency syndrome. J Am Acad Dermatol 1992; 26: 356–359.PubMedCrossRefGoogle Scholar
  33. 33.
    Inwald D, Nelson M, Cramp M, Francis N, Gazzard B. Cutaneous manifestations of mycobacterial infection in patients with AIDS. Br J Dermatol 1994; 130: 111–114.PubMedCrossRefGoogle Scholar
  34. 34.
    Libraty DH, Byrd TF. Cutaneous tuberculosis in the AIDS era: case report and review. Clin Infect Dis 1998; 23: 706–710.Google Scholar
  35. 35.
    Todd J, Fishaut M, Kapral F, Welch T. Toxic-shock syndrome associated with phage-group-I Staphylococci. Lancet 1978; 2 (8100): 1116–8.PubMedCrossRefGoogle Scholar
  36. 36.
    Todd J. Toxic shock syndrome. Clin Microbiol Rev 1988; 1: 432–46.PubMedGoogle Scholar
  37. 37.
    Reingold AL, Hargrett NT, Dan BB, Shands KN, Strickland BY, Broome CV. Nonmenstrual toxic shock syndrome: a review of 130 cases. Ann Intern Med 1982; 96: 871–4.PubMedGoogle Scholar
  38. 38.
    Broome CV, Hayes PS, Ajello GW, Feeley JC, Gibson RJ, Graves LM, Hancock GA, Anderson RL, Highsmith AK, Mackel DC, Hargrett NT, Reingold AL. In vitro studies of interactions between tampons and Staphylococcus aureus. Ann Intern Med 1982; 96: 959–62.PubMedGoogle Scholar
  39. 39.
    Hajjeh RA, Reingold A, Weil A, Shutt K, Schuchat A, Perkins BA. Toxic shock syndrome in the United States: surveillance update, 1979 1996. Emerg Infect Dis 1999; 5: 807–10.PubMedCrossRefGoogle Scholar
  40. 40.
    Toxic shock syndrome. http://www.cdc.gov/epo/dphsi/ casedef/toxicsscurrent.htm.Google Scholar
  41. 41.
    Crowther MA, Ralph ED. Menstrual toxic shock syndrome complicated by persistent bacteremia: case report and review. Clin Infect Dis 1993; 1: 288–9.Google Scholar
  42. 42.
    Stevens DL, Ma Y, Salmi DB, McIndoo E, Wallace RJ, Bryant AE. Impact of antibiotics on expression of virulence-associated exotoxin genes in methicillin-sensitive and meth-icillin-resistant Staphylococcus aureus. J Infect Dis 2007; 195: 202–11.PubMedCrossRefGoogle Scholar
  43. 43.
    Takahashi N, Nishida H, Kato H, Imanishi K, Sakata Y, Uchiyama T. Exanthematous disease induced by toxic shock syndrome toxin 1 in the early neonatal period. Lancet 1998; 351: 1614–9.PubMedCrossRefGoogle Scholar
  44. 44.
    Van Der MeeMarquet N, Lina G, Quentin R, Yaouanc-Lapalle H, Fievre C, Takahashi N, et al. Staphylococcal exanthematous disease in a newborn due to a virulent meth-icillin-resistant Staphylococcus aureus strain containing the TSST-1 gene in Europe: an alert for neonatologists. J Clin Microbiol 2003; 41: 4883–4.PubMedCrossRefGoogle Scholar
  45. 45.
    Cone L, Woodard P, Schlievert P, Tomory G. Clinical and bacteriologic observations of a toxic shock-like syndrome due to Streptococcus pyogenes. N Engl J Med 1987; 317: 146–9.PubMedGoogle Scholar
  46. 46.
    Stevens DL, Tanner MH, Winship J, Swarts R, Ries KM, Schlievert PM, Kaplan E. Severe group A streptococcal infections associated with a toxic shock-like syndrome and scarlet fever toxin A. N Engl J Med. 1989; 321: 1–7.PubMedGoogle Scholar
  47. 47.
    Stevens DL. Life-threatening streptococcal infections: scarlet fever, necrotizing fasciitis, myositis, bacteremia, and streptococcal toxic shock syndrome. In: Stevens DL, Kaplan EL, editors. Streptococcal Infections: clinical aspects, microbiology, and molecular pathogenesis. New York: Oxford University Press; 2000. pp. 163–179.Google Scholar
  48. 48.
    Bisno AL, Stevens DL. Streptococcal infections of skin and soft tissues. N Engl J Med. 1996; 334: 240–5.PubMedCrossRefGoogle Scholar
  49. 49.
    Manders SM. Toxin-mediated streptococcal and staphylococcal disease. J Am Acad Dermatol Venereol 1998; 39: 383–98.Google Scholar
  50. 50.
    Stevens DL. Dilemmas in the treatment of invasive Streptococcus pyogenes infections. Clin Infect Dis 2003; 37: 341–3.PubMedCrossRefGoogle Scholar
  51. 51.
    Darenberg J, Ihendyane N, Sjölin J, Aufwerber E, Haidl S, Follin P, Andersson J, Norrby-Teglung A. StreptIg Study group. Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: a European randomized, double-blind, placebo-controlled trial. Clin Infect Dis 2003; 37: 333–40.Google Scholar
  52. 52.
    Keiser P, Campbell W. ‘Toxic strep syndrome’ associated with group C Streptococcus. Arch Intern Med 1992; 152: 882–884.PubMedCrossRefGoogle Scholar
  53. 53.
    Lu HZ, Weng XH, Zhu B, Li H, Yin YK, Zang YX, Haas DW, Tang YW. Major outbreak of toxic shock-like syndrome caused by Streptococcus mitis. J Clin Microbiol 2003; 41: 3051–5.PubMedCrossRefGoogle Scholar
  54. 54.
    Martino R, Subira M, Manteiga R, Badell I, Argiles B, Sureda A, Brunet S. Viridans streptococcal bacteremia and viridans streptococcal shock syndrome in neutropenic patients: comparison between children and adults receiving chemotherapy or undergoing bone marrow transplantation. Clin Infect Dis 1995; 20: 476–7.PubMedGoogle Scholar
  55. 55.
    Pareja J, gupta K, Koziel H. The toxic shock syndrome and Staphylococcus lugdunensis bacteremia. Ann Intern Med 1998; 128: 603–4.PubMedGoogle Scholar
  56. 56.
    Reich HL, Crawford GH, Pelle MT, james WD. Group B streptococcal toxic shock-like syndrome. Arch Dermatol 2004; 140: 163–6.PubMedCrossRefGoogle Scholar
  57. 57.
    Yavuz T, Parlak AH, Kocabay K. Varicella complicated by scarlet fever. Indian Pediatr 2003; 40: 1002–4.PubMedGoogle Scholar
  58. 58.
    Lina G, Gillet Y, Vandenesch F, Jones ME, Floret D, Etienne J. 1997. Toxin involvement in staphylococcal scalded skin syndrome. Clin Infect Dis 25: 1369–1373.Google Scholar
  59. 59.
    Wang CC, Lo WT, Hsu CF, Chu ML. Enterotoxin B is the predominant toxin involved in staphylococcal scarlet fever in Taiwan. Clin Infect Dis 2004; 38: 1498–502.PubMedCrossRefGoogle Scholar
  60. 60.
    Ladhani S, Joannou CL, Lochrie DP, Evans RW, Poston SM. Clinical, microbial, and biochemical aspects of the exfoliative toxins causing staphylococcal scalded skin syndrome. Clin Microbiol Rev 1999; 12: 224–242.PubMedGoogle Scholar
  61. 61.
    Hanakawa Y, Schechter NM, Lin C, Garza L, Li H, Yamaguchi T, Fudaba Y, Nishifuji K, Sugai M, Amagai M, Stanley JR. Molecular mechanisms of blister formation in bullous impetigo and staphylococcal scalded skin syndrome. J Clin Invest 2002; 110: 53–60.PubMedGoogle Scholar
  62. 62.
    Amagai M, Matsuyoshi N, Wang ZH, Andl C, Stanley JR. Toxin in bullous impetigo and staphylococcal scalded skin syndrome targets desmoglein 1. Nat Med 2000; 6: 1275–7.PubMedCrossRefGoogle Scholar
  63. 63.
    Amagai M, Yamagushi T, Hanakawa Y, Nishifuji K, Sugai M, Stanley JR. Staphylococcal exfoliative toxin B specifically cleaves desmoglein 1. J Invest Dermatol 2002; 118: 845–50.PubMedCrossRefGoogle Scholar
  64. 64.
    Waterhouse R. A case of suprarenal apoplexy. Lancet 1911; 1: 577–8.CrossRefGoogle Scholar
  65. 65.
    Friderichsen C. Waterhouse—Friderichsen syndrome. Acta Endocrinol 1955; 18: 482–92.PubMedGoogle Scholar
  66. 66.
    Ward KM, Celebi JT, Gmyrek R, Grossman ME. Acute infectious purpura fulminans associated with asplenism or hyposplenism. J Am Acad Dermatol 2002; 47: 493–6.PubMedCrossRefGoogle Scholar
  67. 67.
    Francis RB. Acquired purpura fulminans. Semin Thromb Hemost 1990; 16: 310–25.PubMedCrossRefGoogle Scholar
  68. 68.
    Dudgeon DL, Kellog DR, Gilchrist GS, Woolley MM. Purpura fulminans. Arch Surg 1971; 103: 351–8.PubMedGoogle Scholar
  69. 69.
    Kravitz GR, Dries DJ, Peterson ML, Schlievert PM. Purpura fulminans due to Staphylococcus aureus. Clin Infect Dis 2005; 40: 941–7.PubMedCrossRefGoogle Scholar
  70. 70.
    Adem PV, Montgomery CP, Husain AN, Koogler TK, Arangelovich V, Humilier M, Boyle Vavra S, Daum RS. Staphylococcus aureus sepsis and the Waterhouse— Friderichsen syndrome in children. N Engl J Med 2005; 353: 1245–51.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2009

Authors and Affiliations

  • Pascal del Giudice
    • 1
  • Olivier Chosidow
    • 2
  1. 1.Infectiology and Dermatology DepartmentHôpital BonnetFréjusFrance
  2. 2.Université Paris VI and Service de dermatologie et d'allergologieHôpital TenonParisFrance

Personalised recommendations